Antiepileptic drug development program

Cleveland Clinic Quarterly

Volumn 51, Issue 2, 1984, Pages 293-305

  Porter, R J ^a   Cereghino, J J ^a   Gladding, G D ^a   Hessie, B J ^b   Kupferberg, H J ^b   Scoville, B ^b   White, B G ^b  

^a National Institute of Neurological Disorders   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTICONVULSIVE AGENT; BECLAMIDE; BICUCULLINE; CARBAMAZEPINE; CLONAZEPAM; CLORAZEPATE; CLORAZEPATE DIPOTASSIUM; DIAZEPAM; ETHOSUXIMIDE; ETHOTOIN; MEPHENYTOIN; MESUXIMIDE; METHARBITAL; METHYLPHENOBARBITAL; PARAMETHADIONE; PEGANONE; PENTETRAZOLE; PHENACEMIDE; PHENOBARBITAL; PHENSUXIMIDE; PHENYTOIN; PICROTOXIN; PRIMIDONE; STRYCHNINE; THYPHENYTOIN; TRIMETHADIONE; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONVULSION; DRUG DEVELOPMENT; DRUG THERAPY; DRUG TOXICITY; EPILEPSY; HUMAN; INTOXICATION; ORGANIZATION AND MANAGEMENT; SHORT SURVEY; THERAPY;

EID: 0021611548     PISSN: 00098787     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.51.2.293     Document Type: Article

References (0)